Gildan Activewear walks into its Q1 2026 earnings release — scheduled for today, April 30 — already down 7.4% on the week, having sliced through its 200-day moving average earlier in April.
The week's price action sets a bruising backdrop. The stock closed Wednesday at CAD 76.97, with a 2.8% drop in the final session alone. The one-month view is barely positive at 1.9%, meaning the weekly slide has nearly wiped out all of April's gains. Sector peers felt the same broad pressure — LEVI fell 4.1% on the week, COLM dropped 4.2%, and RL lost 4.2% — but GIL underperformed most of them. VFC was the notable outlier, plunging 15.3%, though its situation is structurally different. Within its peer group, Gildan's relative weakness this week is hard to attribute entirely to sector-wide selling.
Short positioning tells a modest but directionally significant story. SI % of free float has climbed to 1.7%, up roughly 5.8% week-on-week and nearly 9% over the past month — a slow, steady build rather than an aggressive directional bet. Borrow costs have also moved, rising 31% over the week to 0.68% APR. That remains inexpensive in absolute terms, but the 54% lift over the past month signals growing demand for borrows heading into the earnings window. Availability is wide, meaning there is no squeeze dynamic in the lending pool, and the short score of 32.6 is unremarkable in the broader universe. The positioning looks cautious rather than crowded — bears are building gradually, not piling in.
The forward earnings picture offers the most constructive data point on the board. The 12-month forward EPS growth estimate ranks in the 93rd percentile of the universe — a standout number that suggests consensus still expects material profit expansion even as the stock retreats. The dividend score ranks at the 99th percentile, though the dividend history in the data runs only to mid-2022, so recent yield figures carry limited practical weight. Valuation has compressed alongside the price: the P/E has drifted to 12.1x and EV/EBITDA to 9.7x, both slipping over the past week. The P/B of 2.4x has also moved lower. UBS reiterated Buy on April 17 with a CAD 110 target — a meaningful premium to current levels — while broader analyst consensus pointed to "Moderate Buy" as of early April. Historical analyst price targets around CAD 80 noted in recent weeks align more closely with the current price; the UBS target looks aggressive from here.
The institutional holder base is broadly domestic and stable. La Caisse de dépôt et placement du Québec reported a 3.1 million-share addition in its latest filing, while Vanguard added 1.6 million and Mackenzie Financial added 2 million. Janus Henderson remains the single largest holder at 5.7%. The pattern suggests conviction among long-only names who added into earlier weakness — a floor of sorts, though institutional flow data carries the usual lag.
The earnings history is short but pointed. At the February 2026 print, the stock fell 4.7% on day one and was down 7.8% five days later. The prior event produced a small bounce of 0.8% on day one but also finished lower over five days. Both recent reactions trended negative at the one-week mark, regardless of the opening-day move.
The print is live today. With the stock already weakened, borrowing costs creeping higher, and the last two post-earnings windows both ending in the red at the five-day mark, what traders watch is whether Gildan's high-percentile forward earnings growth story holds up against tariff pressure in its supply chain — and whether today's number gives bulls a concrete reason to reload.
See the live data behind this article on ORTEX.
Open GIL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
